ATE428732T1 - Gen rekombinante antikörper - Google Patents

Gen rekombinante antikörper

Info

Publication number
ATE428732T1
ATE428732T1 AT99921206T AT99921206T ATE428732T1 AT E428732 T1 ATE428732 T1 AT E428732T1 AT 99921206 T AT99921206 T AT 99921206T AT 99921206 T AT99921206 T AT 99921206T AT E428732 T1 ATE428732 T1 AT E428732T1
Authority
AT
Austria
Prior art keywords
gene recombinant
flt
vegf receptor
relates
present
Prior art date
Application number
AT99921206T
Other languages
English (en)
Inventor
Kenya Shitara
Mikito Ito
Yoko Kawada
Kazuyasu Nakamura
Original Assignee
Kyowa Hakko Kogyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Kk filed Critical Kyowa Hakko Kogyo Kk
Application granted granted Critical
Publication of ATE428732T1 publication Critical patent/ATE428732T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT99921206T 1998-05-20 1999-05-20 Gen rekombinante antikörper ATE428732T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP13900098 1998-05-20
PCT/JP1999/002661 WO1999060025A1 (fr) 1998-05-20 1999-05-20 Anticorps recombines de gene

Publications (1)

Publication Number Publication Date
ATE428732T1 true ATE428732T1 (de) 2009-05-15

Family

ID=15235143

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99921206T ATE428732T1 (de) 1998-05-20 1999-05-20 Gen rekombinante antikörper

Country Status (7)

Country Link
EP (1) EP1086956B1 (de)
AT (1) ATE428732T1 (de)
AU (1) AU767731B2 (de)
CA (1) CA2328986A1 (de)
DE (1) DE69940733D1 (de)
ES (1) ES2325642T3 (de)
WO (1) WO1999060025A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002536968A (ja) * 1999-01-29 2002-11-05 イムクローン システムズ インコーポレイティド Ｋｄｒに特異的な抗体およびその使用
WO2001057067A1 (en) 2000-02-04 2001-08-09 Supratek Pharma Inc. Ligand for vascular endothelial growth factor receptor
US7611711B2 (en) 2001-01-17 2009-11-03 Vegenics Limited VEGFR-3 inhibitor materials and methods
GB0323609D0 (en) * 2003-10-09 2003-11-12 Univ Belfast A peptide,and use of the peptide to assay for sflt-1 protein
JPWO2005035581A1 (ja) * 2003-10-09 2007-11-22 協和醗酵工業株式会社 ヒトＶＥＧＦ受容体Ｆｌｔ−１に特異的に結合する抗体組成物
JP5651893B2 (ja) * 2004-06-07 2015-01-14 協和発酵キリン株式会社 抗ｐｅｒｐ抗体
EP2377555A3 (de) 2004-11-18 2011-11-23 Imclone LLC Antikörper gegen den vaskulären endothelialen Wachstumsfaktorrezeptor-1
RU2482132C2 (ru) * 2005-08-26 2013-05-20 Роше Гликарт Аг Модифицированные антигенсвязывающие молекулы с измененной клеточной сигнальной активностью
KR100998569B1 (ko) * 2008-03-31 2010-12-07 한국원자력연구원 암 또는 전이암 진단 및 치료용 방사면역접합체，및 이를이용한 암 또는 전이암 억제제 개발

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2078539C (en) * 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
JP3565572B2 (ja) * 1992-09-07 2004-09-15 協和醗酵工業株式会社 ヒト化抗体
US5840301A (en) * 1994-02-10 1998-11-24 Imclone Systems Incorporated Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors
ATE283926T1 (de) * 1995-09-11 2004-12-15 Kyowa Hakko Kogyo Kk Antikörper gegen die alpha-kette von humanem interleukin 5 rezeptor
JP3746790B2 (ja) * 1996-11-21 2006-02-15 協和醗酵工業株式会社 抗ヒトＶＥＧＦ受容体Ｆ１ｔ―１モノクローナル抗体

Also Published As

Publication number Publication date
ES2325642T3 (es) 2009-09-10
CA2328986A1 (en) 1999-11-25
EP1086956A4 (de) 2002-08-21
EP1086956A1 (de) 2001-03-28
AU767731B2 (en) 2003-11-20
EP1086956B1 (de) 2009-04-15
WO1999060025A1 (fr) 1999-11-25
DE69940733D1 (de) 2009-05-28
AU3850399A (en) 1999-12-06

Similar Documents

Publication Publication Date Title
EP0882799A4 (de) Gegen humanen vegf-rezeptor flt-1 gerichteter, monoklonaler antikörper.
HRP20190333T1 (hr) Cd20 protutijela s povećanim afinitetom vezanja fc-receptora i povećanom efektorskom funkcijom
EE200700052A (et) Antikeha he v?i mitme apo-lipoproteiin B fragmendi vastu
DE69940733D1 (de) Gen rekombinante antikörper
ATE283926T1 (de) Antikörper gegen die alpha-kette von humanem interleukin 5 rezeptor
CY1112229T1 (el) Αντισωματα κατευθυνομενα εναντι οξειδωμενης απολιποπρωτεϊνης β
DK1411962T3 (da) Terapi for pancreacancer med monoklonalt stof

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties